Cargando…
Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY(®) compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation
Biologics have become an important component of treatment strategies for a variety of diseases, but the immunogenicity of large immune complexes (ICs) and aggregates of biologics may increase risk of adverse events is a concern for biologics and it remains unclear whether large ICs consisting of int...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141648/ https://www.ncbi.nlm.nih.gov/pubmed/37122706 http://dx.doi.org/10.3389/fimmu.2023.1149874 |